Operating Segments

6 Months Ended

Mar. 31, 2012

Operating Segments [Abstract]

Operating Segments

16. Operating Segments

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. Beginning in the first quarter of fiscal 2012, following the sale of SurModics Pharmaceuticals which was previously reported as a separate operating segment, the Company is now organized into two segments, as follows: (1) the Medical Device unit, which is comprised of surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device, with end markets that include coronary, peripheral, and neuro-vascular, and urology, among others, and (2) the In Vitro Diagnostics unit, which consists of component products and technologies for diagnostic test kits and biomedical research applications, with products that include microarray slide technologies, protein stabilization reagents, substrates, and antigens.

The tables below present segment revenue, operating income and depreciation and amortization, as follows (in thousands):

	Three months ended March 31,						Six months ended March 31,
	2012			2011			2012			2011
Revenue:
Medical Device	$	8,753		$	9,978		$	17,620		$	19,813
In Vitro Diagnostics		3,457			3,356			6,506			6,043
Total revenue	$	12,210		$	13,334		$	24,126		$	25,856
Operating income (loss):
Medical Device	$	4,121		$	4,684		$	8,053		$	10,461
In Vitro Diagnostics		1,271			1,182			2,177			1,915
Corporate		(1,703	)		(1,654	)		(3,319	)		(4,043	)
Total operating income	$	3,689		$	4,212		$	6,911		$	8,333
Depreciation and amortization:
Medical Device	$	354		$	418		$	718		$	833
In Vitro Diagnostics		194			199			389			398
Corporate		183			190			373			373
Total depreciation and amortization	$	731		$	807		$	1,480		$	1,604

Segment results above for the six months ended March 31, 2011 include restructuring charges of $0.6 million in Corporate. There were no restructuring charges for the three months ended March 31, 2011 or the three and six months ended March 31, 2012.

Corporate includes expenses for administrative corporate functions, such as executive, corporate accounting, legal, human resources and Board related, that have not been fully allocated to segments. Corporate also includes special charges, such as restructuring costs, which are not specific to a segment.

Asset information by segment is not presented in the table above because the Company does not provide its chief operating decision maker assets by segment, as the data are not readily available.